Background. Vascular endothelial growth factor (VEGF) was recently shown to predict survival in prevalent haemodialysis patients. Soluble VEGF receptors (sVEGFR)-1 and -2 are circulating endogenous modulators of VEGF activity. We thus studied the relationship between sVEGFR-1 and -2 and survival in a cohort of prevalent haemodialysis (HD) patients. Methods. Components of the VEGF system were measured (ELISAs) in 185 prevalent HD patients and levels related to clinical characteristics, biochemical markers and survival. The patients were followed up prospectively for a median 31 (20-37) months. Results. While ischaemic heart disease was independently associated with a lower sVEGFR-2 (OR = 2.75, P = 0.02), sVEGFR-1 was positively associated with IL-6 (ρ = 0.22, P = 0.003) and white blood cell count (ρ = 0.22, P = 0.002). In survival analysis, the patients with a high sVEGFR-1 level had a higher all-cause mortality (Kaplan-Meier ChiSquare = 5.6, P = 0.02) and a higher adjusted mortality risk (Cox HR = 1.93, P = 0.009) than those with low levels. Conclusion. In the first clinical study of sVEGFR-1 and -2 in CKD, we found novel associations between the sVEGFRs and cardiac disease. This may be of clinical importance, as a high sVEGFR-1 was an independent risk factor for allcause mortality.
Introduction
The vascular endothelial growth factor (VEGF) system has an essential role in neoangiogenesis and vascular hyperpermeability [1] [2] [3] [4] . Recently, Mallamaci et al. [5] showed that circulating VEGF levels are associated with left ventricular hypertrophy, systolic dysfunction and a poor outcome in haemodialysis (HD) patients. In non-renal patients, VEGF and its receptors are modulated following cardiac or extremity ischaemia and are essential inducers of neovascularization [6] [7] [8] . In response to pathological conditions such as myocardial infarction and pressure overload, VEGF is secreted from cardiomyocytes and thus contributes to ischaemia-induced neovascularization and reperfusion [3, [9] [10] [11] . However, completed randomized controlled trials of VEGF modulators have not provided convincing evidence of clinical efficacy [12] , perhaps because of the importance of the less studied soluble VEGF receptors 1 (sVEGFR-1, sFlt-1) and sVEGFR-2 (sFlk-1) in modulating VEGF actions [13] . There are as yet no reports investigating the role of soluble VEGF receptors in chronic kidney disease (CKD) patients. We hypothesized that circulating sVEGFR-1 and -2 could help to modulate VEGF signalling, and thus be involved in modulating the recently identified role of VEGF in uraemic cardiovascular complications. We tested this hypothesis in a cohort of 185 prevalent HD patients where prospective follow-up data were available.
Subjects and methods

Study design and patients
The study was performed at the Karolinska University Hospital in Stockholm (including four dialysis units) and at Uppsala Academic Hospital in Uppsala. This was a post hoc analysis from a cross-sectional study originally designed to investigate the variability of inflammatory markers in HD patients [mapping of inflammatory markers in chronic kidney disease (MIMICK) study]. The protocol has previously been described in more detail [14] . From 228 patients completing the original study, 43 patients were excluded because not enough serum was available for analysis, leaving 185 patients (110 males, 59.5%) with a median age of 66 (53-74) years for the present study. The study protocols were approved by the Ethics Committee of Karolinska Institutet Hospital and Uppsala University Hospital. Informed consent was obtained from each patient.
Each patient's medical chart was reviewed by a nephrologist who extracted data pertaining to underlying kidney disease, history of CVD, other comorbid conditions and survival. The comorbidity score of each patient was determined at baseline according to the Davies comorbidity index [15] , which takes into account seven-specified comorbidity domains for patients receiving dialysis: malignancy (21, 11.4%), ischaemic heart disease (IHD) (59, 31.9%), peripheral vascular disease (including cerebrovascular disease) (57, 30.8%), left ventricular heart failure (39, 21.1%), diabetes mellitus (49, 26.5%), systemic collagen vascular disease (13, 7 .0%) and other significant pathology (e.g. cirrhosis) (57, 30.8%). We then grouped Davies scores into low (1-2), median (3) (4) and high (≥5) risk groups. Fifty-nine patients (31.9%) had baseline clinical signs of IHD. Of these, 44 had one or more myocardial infarctions (defined by the presence of chest pain, confirmatory electrocardiograms and enzyme courses), 44 patients had angina pectoris (stable or unstable), 6 patients had undergone percutaneous transluminal coronary angiography and 20 patients had undergone coronary artery by-pass surgery. Sixty-three (34.1%) patients had other vasculopathies without IHD. Of these, 21 patients suffered from cerebrovascular disease (stroke and/or a history of transient ischaemic attack), 14 patients had clinical signs of peripheral vascular disease (ischaemic foot sores or amputation, claudicatio), 17 had left ventricular dysfunction without simultaneous cardiac ischaemia, while 4 patients had been diagnosed with an aortic aneurysm and 7 patients had valvular disease and arrhythmia.
The patients were treated with HD three times a week (3-5 h per session) using bicarbonate dialysate and high-flux (24%) or low-flux (76%) dialysis membranes. Most patients were on antihypertensive medications (β-blockers, n = 93; calcium channel blockers, n = 45; and ACEI/ARB, n = 64), as well as other commonly used drugs in dialysis patients (such as phosphate and potassium binders) and vitamin B, C and D supplementation. Fifty-seven patients were on lipid-lowering medication (statins). A total of 179 patients were on erythropoietin therapy; the median of dose was 10 000 (6000-14 000) IU/week. Subjective global assessment (SGA) was used to evaluate signs of overall protein energy wasting (PEW) [16] . This assessment was completed either at the time of or within 1 week of blood sample collection.
Survival was determined from the day of examination, the end of follow-up on 8 November 2007, with a median follow-up period of 31 (20-37) months. There was no loss of follow-up in any patient. Causes of death were registered by a nephrologist blind to other clinical or biochemical data of the patients.
Laboratory analyses
Blood samples were collected before the HD session after the longest interdialytic period. Plasma and serum were separated and kept frozen at −70 • C if not analysed immediately. Serum concentrations of IL-6 were quantified on the Immulite R automatic analyser (Diagnostic Products Corporation, Los Angeles, CA, USA). C-reactive protein (CRP), leucocytes and serum albumin (bromcresol purple) concentrations were analysed using routine methods at the Department of Laboratory Medicine, Karolinska University Hospital, Huddinge. Serum cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were analysed by standard enzymatic procedures (Boehringer Mannheim, Mannheim, Germany). Low-density lipoprotein (LDL) cholesterol was calculated according to the Friedewald formula [17] .
Serum concentrations of VEGF 165 (PDVE00; R & D Systems, Minneapolis, MN, USA), sVEGFR-1 (DVR100B; R & D Systems) and sVEGFR-2 (DVR200; R & D Systems) were determined in duplicate using commercially available enzyme-linked immunosorbent assay kits. Intra-and inter-assay coefficients of variation for VEGF, sVEGFR-1 and sVEGFR-2 kits were 6.7% and 8.8%, 3.8% and 9.8%, 4.2% and 7.0%, respectively.
Statistical analyses
All variables were expressed as mean ± SD or as median (interquartile range, IQR), unless otherwise indicated. Statistical significance was set at the level of P < 0.05. Comparisons between two groups were assessed with Student's unpaired t-test and the Mann-Whitney test or the χ 2 test, as appropriate. Differences among more than two groups were analysed by analysis of variance (ANOVA) using one-way ANOVA or the KruskalWallis test, as appropriate, followed by a post hoc test if ANOVA was significant. Spearman's rank correlation (ρ) was used to determine correlations between VEGF, sVEGFR-1 and sVEGFR-2 and other variables. Multinomial logistic regression analysis was used to assess the predictors for IHD, and other vasculopathies. Survival analyses were made using Kaplan-Meier survival curves and a Cox proportional hazards model. Univariate and multivariate Cox regression analyses were presented as hazard ratios [HR; 95% confidence intervals (CI)]. Furthermore, we performed a ROC analysis to determine cut-off points for IL-6, VEGF, sVEGFR-1 and sVEGFR-2 giving maximum sensitivity and specificity for the outcome of all-cause mortality. Only IL-6 (7.0 pg/mL, AUC = 0.69, sensitivity 79%, specificity 52.2%, P < 0.001) and sVEGFR-1 (141.5 pg/mL, AUC = 0.62, sensitivity 63%, specificity 54%, P = 0.03) yielded significant cut-offs, which were used to define inflamed and non-inflamed patients (IL-6) and high-and low-risk sVEGFR-1 groups, respectively. For sVEGFR-2 and VEGF, we instead opted to calculate models using median, tertile and quartile groups. Age groups were defined as follows: low (<45 years old), middle (45-64 years old) and old (≥65 years). All statistical analyses were performed using the statistical software SPSS version 14.0 (SPSS Inc., IL, USA). 
Results
sVEGFR-1, sVEGFR-2 and VEGF levels in HD patients
The baseline characteristics of the 185 HD patients are summarized in Table 1 , grouped according to the CVD status. Median serum levels for the measured proteins in the 185 prevalent HD patients were for sVEGFR-1 137.5 (108.3-186.8) pg/mL, for sVEGFR-2 8634 (7527 -10437) pg/mL and for VEGF 221.0 (109.5-390.0) pg/mL. Of note, patients with IHD had lower levels of sVEGFR-2 than both patients with CVD but no known IHD and those without CVD, while there was no difference in sVEGFR-1 or VEGF concentrations. There were also no differences in circulating VEGF, sVEGFR-1 or sVEGFR-2 between diabetic and non-diabetic patients, male and female patients, or among patients in different Davies comorbidity risk groups (data not shown).
Univariate correlations for sVEGFR-1, sVEGFR-2 and VEGF levels in HD patients
The univariate correlates for sVEGFR-1, sVEGFR-2 and VEGF levels in HD patients are shown in Table 2 . Interestingly, there were no significant associations between VEGF and its receptors sVEGFR-1 or sVEGFR-2. No correlations were observed among EPO dose, VEGF and VEGF receptors (data not shown). Table 3 shows a multivariate multinominal regression model predicting IHD. After adjustment for age, sex, dialysis vintage, IL-6, triglycerides, sVEGFR-1 and VEGF, a sVEGFR-2 below the median was still associated with IHD. It should be noted that using tertiles or quartiles to group VEGF or sVEGFR-2 made the whole model lose its significance, wherefore only data using median groups are shown.
sVEGFR-2 as a predictor of IHD
Survival analysis
During the median follow-up period of 31 (20-37) months, 72 patients died. Causes of death included myocardial infarction (n = 9); other types of cardiac failure (n = 7); sudden death (n = 9); cerebral thrombotic or haemorrhagic stroke (n = 5); pulmonary infection (n = 4); septicaemia (n = 6); malignant disease (n = 4); aneurysm (n = 1); withdrawal from RRT (n = 8); and other reasons (n = 19). Kaplan-Meier analysis (Figure 1) showed that patients with a high sVEGFR-1 level had a higher 0.002 −0.003 0.018 * P < 0.05; * * P < 0.01 CRP, C-reactive protein; CHOL, total serum cholesterol; TG, fasting serum triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol. After adjustment for age groups, sex, dialysis vintage, VEGF (< versus ≥221.0 pg/mL), sVEGFR-1 (< versus ≥141.5 pg/mL), IL-6 (< versus ≥7.0 pg/mL) and triglycerides. Whole model adjusted r 2 = 0.317, P < 0.001 Table 4 . Hazard ratios for all-cause mortality in 185 HD patients obtained from a Cox proportional hazards model
Hazard ratio P-value 95% Confidence interval Crude sVEGFR-1 (below versus above 141.5 pg/mL) 1.75 P = 0.02 1.09-2.79 Adjusted sVEGFR-1 (below versus above 141.5 pg/mL) 1.93 P = 0.009 1.18-3.1
After adjustment for age groups, sex, dialysis vintage, VEGF (< versus ≥221.0 pg/mL), sVEGFR-2 (< versus ≥8634 pg/mL), IL-6 (< versus ≥7.0 pg/mL) and Davies comorbidity score groups. Whole model likelihood ratio (χ 2 ) = 71.2, P < 0.001. Fig. 1 . Kaplan-Meier survival curves for patients with sVEGFR-1 above or below the ROC-derived cut-off for all-cause mortality in 185 HD patients followed for a median of 31 months.
all-cause mortality (Chi-Square = 5.6, P = 0.02) than those with a low sVEGFR-1 level. No survival differences were found between the VEGF or sVEGFR-2 groups. Analysing VEGF groups as predictors of survival only in patients without known IHD did not alter this finding. In a Cox proportional hazards model (Table 4 ) of allcause mortality, high sVEGFR-1 levels were associated with all-cause death also following adjustment for age, sex, dialysis vintage, IL-6, Davies score, sVEGFR-2 and VEGF.
Discussion
In the present study, we investigated putative links of VEGF and its soluble receptors sVEGFR-1 and -2 with CVD and mortality in prevalent HD patients. We found that a high sVEGFR-1 was associated with inflammation. Also, a high level of sVEGFR-1 was an independent risk factor for all-cause mortality, while a low sVEGFR-2 was independently associated with IHD. Our findings directly relate to the recently published study by Mallamaci et al. [5] , who showed that in 228 prevalent HD patients, circulating VEGF predicted LVH and mortality risk in a manner related to inflammation and nitric oxide. VEGF, which was originally described as a permeability factor [2, 3] , is an essential cytokine for endothelial proliferation, migration and tube formation [3] . Furthermore, VEGF functions as a potent survival factor for endothelial cells during physiological and pathological angiogenesis [18, 19] and induces endothelial nitric oxide synthase (eNOS) to regulate vasodilatory responses [20, 21] . Recent studies have demonstrated that in vivo, VEGF signalling is tightly regulated by two cell-surface receptors, VEGFR-1 and VEGFR-2 [22] . While VEGFR-1 is expressed in both endothelial cells and macrophagelineage cells [23] , VEGFR-2 is exclusively expressed by endothelial cells and is the major signal transducer for VEGF-induced angiogenesis [22, 24, 25] . These are also present in the circulation as soluble VEGFR-1 and -2, perhaps due to alternative mRNA splicing [26, 27] or cell surface shedding [28] . sVEGFR-1 not only plays a negative role in angiogenesis, but also promotes inflammation [23, 29, 30] . In contrast to sVEGFR-1, little is known about sVEGFR-2, but previous studies suggest that it also has anti-angiogenic properties [13] .
The present study is to our knowledge the first to assess the levels of soluble VEGF receptors in patients with CKD. We report that in patients with IHD, but not in those with pure non-IHD, sVEGFR-2 is lower while sVEGFR-1 and VEGF are not different. This link between low sVEGFR2 and IHD was present also after adjustment for age, sex, dialysis vintage, IL-6, triglycerides, sVEGFR-1 and VEGF. As sVEGFR-2 may function as a VEGF antagonist [13, 28] , our data support the findings by Mallamaci et al. [5] of a positive correlation between VEGF and LVH. We speculate that a decreased level of sVEGFR-2, the soluble form of the major VEGF pro-angiogenic signal transducer [22] , is a physiological response to ischaemia, designed to increase angiogenesis. On the other hand, VEGF signalling through the membranous isoform of VEGFR-2 is essential for endothelial cell function and survival [5] . As sVEGFR-2 has been suggested to derive mainly from shedding from endothelial cell surfaces [28] , a low sVEGFR-2 may instead reflect reduced cellular VEGFR-2 and/or other forms of endothelial damage. Indeed, the study by Mallamaci et al. [5] found that adjustment for the nitric oxide synthase inhibitor ADMA abrogated the association between VEGF and LVH. A similar finding was also demonstrated by Chaiworapongsa et al. [31] who found that preeclamptic endothelial dysfunction correlated with lower sVEGFR-2 levels.
As it is expressed in both endothelial cells and macrophages [23] , VEGFR-1 has been linked to inflammation [23, 29] , and is also altered in non-uraemic CVD [6, 7, 32] . We found sVEGFR-1 to correlate positively with inflammation, but could not show a direct link to CVD. However, a high sVEGFR-1 was independently associated with an increased risk of all-cause mortality. sVEGFR-1 likely acts as an endogenous antagonist for VEGF and as a negative regulator of post-ischaemic angiogenesis and reperfusion [13] . Both in vitro [33] and in vivo [34] , elevated sVEGFR-1 has been shown to impair the vasodilation response and to cause proteinuria. Thus, both sVEGFR-1 and -2 likely regulate VEGF action on endothelial cells [22] , which in turn is associated with endothelial dysfunction [5] , a condition highly prevalent in CKD [35] and an important predictor of outcome [36, 37] .
Surprisingly, we failed to replicate the previously published [5] finding of an association between VEGF itself and survival. While the levels measured in our study (median 221.0 pg/mL, range 109.5-390.0 pg/mL) correlate with those reported in the other study (median 276 pg/mL), both studies were carried out using serum samples. Unfortunately, as a significant and highly variable platelet-mediated secretion of VEGF during the clotting process has been reported [38] , serum sampling may thus give highly variable results that may be one cause for our lack of significant findings. Indeed, VEGF did not correlate with either IL-6, albumin or inflammation, something that we would have expected based upon previous findings [5] .
In summary, we assessed circulating sVEGFR-1 and -2 in 185 prevalent HD patients for what we believe to be the first time. We report novel associations between these receptors and CVD, especially IHD. Furthermore, we show that a high sVEGFR-1 is a predictor of all cause mortality in these patients.
